Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs - ACR Meeting Abstracts
Por um escritor misterioso
Descrição
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research describing ASDAS LDA achievement among patients treated with biologic DMARDs (bDMARD) is limited. The aim of this study was to describe disease activity and patient-reported outcome measures (PROMs) among patients […]
Frontiers Targeted Therapies in Axial Psoriatic Arthritis
Frontiers Residual Pain in the Context of Selecting and
Canadian Rheumatology Association Meeting Quebec City Convention
Canadian Rheumatology Association Meeting Quebec City Convention
PDF) Effectiveness and safety of adalimumab in patients with
Efficacy and safety of upadacitinib in patients with active
Safety Profile, Axial Spondyloarthritis
Assessment and Monitoring, Ankylosing Spondylitis
ASAS-HI improvement ≥30%, ASDAS LDA status and ASAS40 response
Frontiers Residual Pain in the Context of Selecting and
de
por adulto (o preço varia de acordo com o tamanho do grupo)
